Citation tools
"N-Terminal Modification of the Tetrapeptide Arg-Leu-Tyr-Glu, a Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Antagonist, Improves Antitumor Activity by Increasing its Stability against Serum Peptidases." Molecular Pharmacology
96.6
(2019):
692-701.
Web. 26 Feb. 2021.